- Home
- PGNY vs DNTH Comparison
PGNY vs DNTH Comparison
Compare PGNY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGNY | DNTH |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PGNY | DNTH |
|---|---|---|
| Price | $20.77 | $47.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $27.90 | ★ $71.22 |
| AVG Volume (30 Days) | ★ 1.4M | 848.2K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.96 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,268,689,000.00 | $3,078,000.00 |
| Revenue This Year | $11.63 | N/A |
| Revenue Next Year | $9.52 | N/A |
| P/E Ratio | $33.99 | ★ N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $17.98 | $13.37 |
| 52 Week High | $28.75 | $57.50 |
Technical Indicators
Market Signals| Indicator | PGNY | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 49.28 |
| Support Level | $20.75 | $45.64 |
| Resistance Level | $21.75 | $53.33 |
| Average True Range (ATR) | 0.85 | 3.16 |
| MACD | -0.26 | -0.67 |
| Stochastic Oscillator | 11.18 | 17.79 |
Price Performance
Historical ComparisonAbout PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.